Net Loss of Aspira Pathlab & Diagnostics reported to Rs 0.50 crore in the quarter ended March 2024 as against net loss of Rs 0.26 crore during the previous quarter ended March 2023. Sales rose 12.02% to Rs 3.82 crore in the quarter ended March 2024 as against Rs 3.41 crore during the previous quarter ended March 2023.For the full year,net loss reported to Rs 2.67 crore in the year ended March 2024 as against net loss of Rs 0.09 crore during the previous year ended March 2023. Sales declined 8.71% to Rs 13.20 crore in the year ended March 2024 as against Rs 14.46 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales3.823.41 12 13.2014.46 -9 OPM %-3.144.40 --8.9411.07 - PBDT-0.120.12 PL -1.131.50 PL PBT-0.50-0.26 -92 -2.67-0.09 -2867 NP-0.50-0.26 -92 -2.67-0.09 -2867 Powered by Capital Market - Live News

Aspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 28 May 2024Powered by Capital Market - Live News

Net loss of Aspira Pathlab & Diagnostics reported to Rs 0.74 crore in the quarter ended December 2023 as against net profit of Rs 0.44 crore during the previous quarter ended December 2022. Sales declined 20.82% to Rs 3.46 crore in the quarter ended December 2023 as against Rs 4.37 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales3.464.37 -21 OPM %-10.6918.54 - PBDT-0.360.83 PL PBT-0.740.44 PL NP-0.740.44 PL Powered by Capital Market - Live News

Aspira Pathlab & Diagnostics has revised the meeting of the Board of Directors which was scheduled to be held on 10 February 2024. The meeting will now be held on a later date.Powered by Capital Market - Live News

Aspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 10 February 2024.Powered by Capital Market - Live News